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The P2X7 receptor and pannexin-1 
are involved in glucose-induced 
autocrine regulation in β-cells
Marco Tozzi, Anna T. Larsen, Sofie C. Lange, Andrea Giannuzzo, Martin N. Andersen &  
Ivana Novak  
Extracellular ATP is an important short-range signaling molecule that promotes various physiological 
responses virtually in all cell types, including pancreatic β-cells. It is well documented that pancreatic 
β-cells release ATP through exocytosis of insulin granules upon glucose stimulation. We hypothesized 
that glucose might stimulate ATP release through other non-vesicular mechanisms. Several purinergic 
receptors are found in β-cells and there is increasing evidence that purinergic signaling regulates 
β-cell functions and survival. One of the receptors that may be relevant is the P2X7 receptor, but its 
detailed role in β-cell physiology is unclear. In this study we investigated roles of the P2X7 receptor 
and pannexin-1 in ATP release, intracellular ATP, Ca2+ signals, insulin release and cell proliferation/
survival in β-cells. Results show that glucose induces rapid release of ATP and significant fraction of 
release involves the P2X7 receptor and pannexin-1, both expressed in INS-1E cells, rat and mouse 
β-cells. Furthermore, we provide pharmacological evidence that extracellular ATP, via P2X7 receptor, 
stimulates Ca2+ transients and cell proliferation in INS-1E cells and insulin secretion in INS-1E cells and 
rat islets. These data indicate that the P2X7 receptor and pannexin-1 have important functions in β-cell 
physiology, and should be considered in understanding and treatment of diabetes.
Pancreatic β-cells are the only source of insulin in the body, and thus they have a key role in whole body metabolic 
homeostasis. Regulation of insulin secretion is complex; intracellular ATP has a central role, but there is now 
solid evidence that also extracellular ATP is an important regulator of β-cell functions. For example, extracellu-
lar nucleotides/sides can evoke insulin secretion, also independently of glucose, and this response is preserved 
in type-2 diabetes models1. There are two potential sources of extracellular ATP for stimulating β-cells: ATP 
co-releases with transmitters from nerve terminals, and ATP released from insulin-containing granules2–5. In 
particular, the latter process is well investigated and it has been shown that ATP is stored in vesicles and upon 
release can reach local concentrations in micromolar range2–5. However, it appears that release of small molecules 
like ATP (and GABA) precedes release of peptide cargo and acts with positive feedback/autocrine stimulation6,7. 
Accumulation of ATP into vesicles is thought to occur via vesicular nucleotide transporter, VNUT/SLC17A9, and 
knockdown of VNUT leads to diminished glucose-responsive ATP release, though described effects on insulin 
release are disparate8,9. Moreover, it cannot be excluded that β-cells can also release ATP by other mechanisms, 
which can include connexins, pannexin-1, maxi-anion channels, cell volume and mechanosensitive pathways10,11. 
In particular, several recent studies focus on pannexin-1 as a major ATP efflux pathway12,13. Thorough investiga-
tions of such alternative ATP-release pathways in β-cells are pending until now.
The pancreatic β-cells express a number of purinergic P2 (and adenosine) receptors that have different effects 
on cell functions. In rodent β-cells and pancreas the P2Y1 and P2Y6 receptors stimulate insulin secretion14, while 
the mouse P2Y13 receptor inhibits secretion15 and also causes glucolipotoxicity16,17. In human β-cells, recent stud-
ies indicate that the P2X3 receptor regulates insulin secretion in an autocrine fashion18, though the P2Y1 receptor 
as a key receptor in autocrine regulation of mouse and human cells has been revived19,20. Regarding regulation of 
β-cells mass, the number of studies are not yet extensive but proliferative, cytoprotective and apoptotic function 
of some receptors, for example, P2Y6 and P2Y13 receptors, have been described17,21,22.
One interesting and potentially important receptor is the P2X7 receptor (P2X7R) because it plays a central 
role in both health and a wide spectrum of disorders, such as central nervous system diseases, pain, osteoporosis, 
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cancer and inflammation23–27. The receptor is highly polymorphic and recent studies show that several single 
nucleotide polymorphisms (SNPs) in the receptor are associated with osteoporosis, multiple myeloma, leu-
kemia, pain and bipolar diseases28–32. The P2X7R has different modes of operation (cation-selective channels vs. 
large lytic pores); and it plays a dual role in cell survival (proliferation vs. cell death) as initially described by Di 
Virgilio’s group on lymphocytes/lymphoid cells33,34 and confirmed by many others on a variety of cells35–40. Since 
the P2X7R is a key receptor in inflammation and it is expressed in immune cells41, it has been ascribed a role in 
inflammation and diabetes1,25,27,42. Based on studies of P2X7R expressing lymphocytes in non-obese diabetic 
(NOD) mice, it was proposed that the receptor is an important candidate in type-1 diabetes in these mice43,44. 
Further, a knockout of the P2X7R prevented streptozotocin-induced type-1 diabetes in mice45, and targeting the 
receptor in T-cells with the inhibitor, oxidized-ATP, delayed islet allograft rejection46.
Whether the P2X7R is expressed in β-cells and which function it may have is not entirely clear. Some studies 
report immunolocalization of the P2X7R in rodent α-cells and others in β-cells47–49. However, the P2X7R was 
detected on mRNA and protein level in the rat β-cell line INS-1E, but the potentiating and inhibitory effects on 
insulin secretion were ascribed to P2Y4 and P2X3 receptors, respectively50. A P2X7-like receptor was reported 
for the hamster cell line HIT-T15, where its stimulation induced cation fluxes, pore formation and apoptosis after 
24 h of stimulation51. P2X7R knockout mice had lower β-cell mass, impaired glucose tolerance and defective insu-
lin and IL-1β and IL-1Ra secretion49. The P2X7R was found by in situ hybridization in human islets, where ATP 
increased insulin secretion, while unspecific blockers BBG and KN-62 had insignificant effects on insulin secre-
tion18. The authors favored the interpretation that the P2X3 receptor was the main autocrine signaling pathway. 
A recent study indicates that variations in glucose homeostasis traits are associated with P2X7R polymorphisms 
Figure 1. Expression of P2X7R and Panx1 in INS-1E cells. (a) Representative gel of P2X7 and Panx1 mRNA 
expression. (b) Representative Western blot of P2X7R and Panx1 expression in INS-1E cells grown in increasing 
glucose concentrations. Loading control was β-actin. The images (in a and b) are cropped from original full-
length gels and blots that are shown in the supplementary material. (c,d) Western blot quantification of P2X7R 
and Panx1 (isoform A and D) expression in INS-1E cells grown in increasing glucose concentrations. The ratio 
of protein (P2X7R or Panx1) to β-actin were normalized to 2.8 mM glucose. Data represent means ± s.e.m. and 
n denotes the number of independent experiments and significant differences *p < 0.05 and **p < 0.01 are 
indicated.
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in humans and mice52. In particular, hypoactive SNP polymorphism (P451L) in mice leads to different glucose 
regulation under stress (glucose and insulin tolerance tests), which may reflect changes in inflammasome acti-
vation, release of cytokines and other indirect effects. Again, the role of P2X7R in immune system rather than in 
β-cells has been considered.
The aim of this study was to establish whether β-cells express functional P2X7 receptors and pannexin-1 
(Panx1) and to determine whether these proteins play roles in ATP release, insulin secretion and cell survival. 
For this purpose we used INS-1E β-cell line, which is well established as a model for mechanistic studies. We find 
that glucose stimulated ATP release, which is sensitive to P2X7R and Panx1 inhibition, and that further autocrine 
signaling via the P2X7R affects calcium signaling, insulin secretion and β-cell proliferation.
Results
Expression of the P2X7 receptor and pannexin-1. Since P2X7R and Panx1 might be associated with 
ATP release, we first investigated whether these are expressed on mRNA and protein levels in INS-1E cells 
(Fig. 1). The PCR product shows that P2X7 and Panx1 are expressed in INS-1E cells (Fig. 1a). Protein expression 
of P2X7R and Panx1 in response to increasing glucose concentrations was determined using western blot and 
results are shown in Fig. 1b,c. The antibody against the intracellular C-terminal part of P2X7R recognized the 
full length isoform at about 75 kDa (Fig. 1b,c). Quantification of the full length P2X7R isoform shows that cells 
grown in high glucose (16.7 mM) for 48 h upregulate P2X7R expression compared to cells grown in low glucose 
(2.8 mM) (Fig. 1c). Anti-pannexin-1 antibody recognized three isoforms of the protein at around 48, 42 and 
35 kDa, corresponding, respectively, to the three known rat isoforms (A, C and D)(Fig. 1b)53. Both Panx1A and 
D were strongly expressed and the expression of both isoforms was upregulated with increased glucose concen-
trations after 24 and 48 h (Fig. 1d).
Localization of P2X7R and Panx1 in INS-1E cells as well as in native rat and mouse islets is shown by immu-
nofluorescence in Fig. 2. The two proteins are expressed on all INS-1E cells as shown by representative images 
on cell colonies in Fig. 2a,e. The P2X7R is expressed weakly on plasma membranes in cluster-like formations 
Figure 2. Immunolocalization of P2X7R and Panx1 in INS-1E cells, rat and mouse pancreas. Overlay images of 
INS-1E cells stained for P2X7R (a–d) and Panx1 (e–h) (green), insulin (red) and nuclei were stained with DAPI 
(blue). Co-localization graphs (d,h) show co-localization of P2X7R or Panx1 and insulin in corresponding 
images to the left (c,g). Person’s coefficient was x and y. Arrows indicate localization of the two proteins in 
the plasma membrane. Rat pancreas (i,j) and mouse pancreas (k,l) was stained for P2X7R (i,k) or Panx1 (j,l) 
(green) as above. All bars are 25 µm. Images shown here are representative of 3–10 images per slide on 3–9 
independent staining experiments.
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Figure 3. Effect of glucose, mannitol, metabolic and transport inhibitors on ATP release and intracellular 
ATP. (a) The time-course of ATP release after stimulation with 16.7 mM glucose and corresponding control 
(5.5 mM glucose). The arrow indicates stimulus application. (b) ATP released in response to increasing 
glucose concentrations shown as the difference between the basal extracellular ATP (in 2.8 mM glucose) 
and the peak release with the indicated glucose concentrations. (c) ATP release in response to high glucose 
(Glu) and mannitol (Man). The control glucose concentration was 5.5 mM and data show the difference in 
extracellular ATP before and after stimulation with the indicated factors. (d) Cell volume was measured as 
relative fluorescence intensity of calcein. The arrow indicates stimulation with 5.5 mM glucose, 16.7 mM 
glucose, 16.7 mM mannitol or hypotonic solutions. A decrease in fluorescence intensity indicates cell volume 
increases. Responses in each cell were normalized to the average of the baseline and corrected for bleaching. 
(e,f) The difference in extracellular ATP before and after stimulation with 16.7 mM glucose alone or in 
combination with a pre-treatment with the indicated inhibitors: AZ10606120 (10 μM), A438079 (10 μM), 10Panx 
(100 μM), glyoxylate (50 μM), bafilomycin A (1 μM), FCCP (5 μM) or 3-O-methylglucose. (h) Intracellular 
www.nature.com/scientificreports/
5SCIeNTIfIC RepoRts |  (2018) 8:8926  | DOI:10.1038/s41598-018-27281-9
(Fig. 2b,c arrows). These “clusters” may be located to lipid rafts, as is known to be the case for this receptor54,55. 
Furthermore, P2X7R is also found intracellulary in organelles most likely associated with receptor synthesis or 
endocytosis. We observed similar expression of recombinant rat P2X7R tagged with GFP in HEK293 cells56. 
On a whole-cell level analysis we found that there is weak co-localization of the P2X7R and insulin as shown in 
Fig. 2d (Pearson´s correlation coefficient of 0.13). In 16 images analyzed, the Pearson´s correlation coefficient 
was 0.24 ± 0.07. In contrast to P2X7R, Panx1 is strongly expressed on the plasma membrane (Fig. 2e,f) but some 
clusters are also present on the plasma membrane and intracellularly. The high-resolution image (Fig. 2g) and 
co-localization analysis (Fig. 2h, Pearson’s correlation coefficient of 0.10) indicate weak co-localization with insu-
lin vesicles. In 13 images analyzed the coefficient was 0.20 ± 0.02. Figure 2i,j shows P2X7R and Panx1 immunore-
activity in rat islets, respectively, and Fig. 2k,l show the two proteins in mouse islets.
Glucose stimulates fast ATP release that depends on the P2X7 receptor and pannexin-1. Since 
pancreatic β-cells are exposed to various concentrations of blood glucose, we tested whether changes in glu-
cose concentration affect ATP release in INS-1E cells. Figure 3a shows online live-cell measurement of ATP 
release. Note that addition of an equivalent volume of solution containing 5.5 mM glucose evoked a small ATP 
release, most likely due to mechanical disturbance caused by pipetting. Mechanical sensitivity of β-cells is shown 
in Supplementary Fig. 1. Nevertheless, an increase in the glucose concentration to 16.7 mM induced a rapid and 
large increase in the extracellular concentration of ATP (Fig. 3a). Furthermore, stimulating the cells with increas-
ing glucose concentrations ranging from 2.8 mM glucose to 25 mM showed a dose-dependent increase in the ATP 
release (Fig. 3b).
We hypothesized that the rapid glucose effect on ATP release could be due to osmotic changes. Therefore, in 
another series of experiments we tested an equivalent concentration of mannitol and data are shown in Fig. 3c. 
Both 16.7 mM glucose and 16.7 mM mannitol induced ATP release. Next, we monitored cell volume changes with 
calcein. Figure 3d shows that glucose had no significant effect on cell volume, while mannitol caused transient 
cell volume decrease (fluorescence increase) followed by cell volume recovery. As a control for cell volume meas-
urements, we exposed INS-1E cells to hypotonic solution. This caused cell swelling (fluorescence decrease), tran-
sient cell volume recovery, and then swelling/loss of fluorophore with prolonged hypotonic exposure. Therefore, 
although hyperosmotic stress (mannitol) could induce ATP release, ATP release due to equiosmolar glucose is not 
likely due to osmotic changes, as presumably glucose enters the cells and would be rapidly metabolized.
In the following series of experiments we studied ATP release mechanisms. As shown in Fig.  3e, 
glucose-stimulated ATP release was significantly diminished by the P2X7R inhibitor AZ10606120. Another 
inhibitor (A438079) also appeared to reduce ATP release, though the effect was not significant. The pannexin-1 
mimetic inhibitory peptide 10Panx also significantly reduced glucose-stimulated ATP release (Fig. 3e). Glyoxylate, 
a putative inhibitor of vesicular nucleotide transporter (VNUT) and bafilomycin A, a V-ATPase inhibitor, both 
inhibited ATP release which indicates that also vesicular exocytosis could be involved in ATP release. However, 
none of the tested inhibitors had any significant effect on mannitol-stimulated ATP release (Supplementary 
Fig. 1). These results indicate that indeed glucose and mannitol stimulate ATP release through different 
mechanisms.
Furthermore, we investigated the role of glucose transport and metabolism on ATP release using the 
non-metabolizable glucose analogue 3-OMG and the mitochondrial uncoupler FCCP (Fig. 3f). Addition of 
FCCP or 16.7 mM 3-OMG induced significantly less ATP release compared to the corresponding concentration 
of glucose. We hypothesized that ATP release process correlates with intracellular ATP levels and therefore we 
measured intracellular ATP levels at the time-point when we detected peak ATP release. Indeed, as shown in 
Fig. 3g, 16.7 mM glucose increased intracellular ATP content compared to the control (5.5 mM glucose) and 
FCCP dramatically decreased it both in low and high glucose conditions. Addition of 16.7 mM 3-OMG did not 
increase intracellular ATP above the control level, thus indicating that glucose transport and metabolism was 
lower, and again correlated with lower ATP release. Lastly, inhibition of Panx1 and P2X7R significantly inhibited 
the high glucose-induced increase in intracellular ATP level, indicating that purinergic signaling was important 
in maintaining intracellular ATP as well as ATP release (Fig. 3e,g).
P2X7R stimulates calcium responses and insulin secretion. To investigate the role of P2X7R in insu-
lin secretion, we measured 30-min insulin secretion in INS-1E cells after P2X7R activation in low and high glu-
cose concentrations. The P2X7R agonist BzATP (2′-3′-O-(4-benzoylbenzoyl)-ATP, 10 μM) significantly increased 
insulin secretion in both glucose concentrations (Fig. 4a). Perhaps surprisingly, the P2X7R inhibitor AZ10606120 
had no significant effect on the insulin secretion in the two glucose concentrations.
We furthermore evaluated the role of the P2X7R in insulin secretion in isolated rat islets and Fig. 4b shows 
that at low glucose concentrations BzATP (10 μM) potentiated insulin secretion. Basal insulin secretion in 
2.8 mM glucose was 0.93 ± 0.18 ng insulin/(islet*30 min) and insulin secretion in the presence of BzATP was 
3.2 ± 1.1 ng insulin/(islet*30 min)(n = 5–7). High glucose concentrations (16.7 mM) increased insulin secretion 
to 5.7 ± 1.1 ng insulin/(islet*30 min) but BzATP had no further effect, most likely because β-cells were maximally 
stimulated.
It is well established that insulin secretion is activated by changes in intracellular Ca2+. Therefore, we inves-
tigated the effect of BzATP on intracellular Ca2+ signals in INS-1E cells loaded with Fura-2. Figure 5a shows 
ATP was measured in cells incubated with 5.5 mM glucose (control) or 16.7 mM glucose with or without 
inhibitors as indicated. Data are normalized to the response with 16.7 mM glucose. All data are shown as mean 
values ± s.e.m. and significance is indicated *p < 0.05 and **p < 0.01.
www.nature.com/scientificreports/
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that addition of 10 μM BzATP in 2.8 mM glucose buffer induced Ca2+ transients that were synchronized. 
Pre-treatment with the P2X7R inhibitor AZ10606120 almost abolished the synchronized Ca2+ transient 
(Fig. 5b,e), but Fura-2 signal indicated that intracellular Ca2+ was more unsteady (Fig. 5b). High glucose concen-
tration (16.7 mM) induced characteristic Ca2+ oscillations in many cells, and addition of BzATP on top resulted in 
additional synchronized Ca2+ transients, which were abolished in cells pre-treated with the inhibitor (Fig. 5b,d). 
As a positive control at the end of the experiment, INS-1E cells were exposed to 30 mM K+, which is known to 
depolarize cell membrane voltage and increase Ca2+ influx via voltage-sensitive Ca2+ channels. The data showing 
effect of BzATP with/without AZ10606120 and K+ step are summarized in Fig. 5e,f.
In additional series of experiments we tested whether extracellular ATP, released from cells in high-glucose 
conditions, could contribute to Ca2+ transients. Figure 6a,b shows that addition of apyrase to high-glucose solu-
tion was able to decrease the height of Ca2+ oscillations. Moreover, addition of BzATP had not much effect, most 
likely because it was hydrolyzed by apyrase. The K+ step though evoked expected Ca2+ increase. The P2X7R inhib-
itor, AZ10606120, had similar effect as apyrase on diminishing the Ca2+ oscillations induced by high-glucose 
(Fig. 6c,d). However, with prolonged exposure to AZ10606120 the Fura-2 ratio increased by about 0.3–0.6 
Figure 4. Role of P2X7R on insulin secretion in INS1-E cells and pancreatic islets. (a) Data show the effect 
of the P2X7R agonist BzATP (10 μM) or AZ10606120 (10 μM) on 30 min insulin secretion in INS1-E cells. 
Data are normalized to 2.8 mM glucose and show mean values ± s.e.m. of indicated number of independent 
experiments, and p-values are indicated. (b) Insulin secretion from pancreatic islets during 30 min stimulation 
with glucose, BzATP (10 μM) or AZ10606120 (10 μM). Data are normalized to 2.8 mM glucose and show mean 
values ± s.e.m. of the indicated number of experiments, and p-values are indicated.
www.nature.com/scientificreports/
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(n = 4), indicating that the level of intracellular Ca2+ was rising. This was even more pronounced in cells that were 
pre-treated with AZ10606120 for about 30 min before Fura-2 imaging was started (data not shown). Furthermore, 
in the P2X7R inhibitor experiments, BzATP and K+ step had only small effects (Fig. 6c,d). Nevertheless, within 
experimental time frame INS-1E cells appeared healthy and Ca2+ signal recovered when cells were exposed to 
control 2.8 mM solution (Fig. 6c).
P2X7R affects cell proliferation. In the following series of experiments we studied the effect of activation 
or inhibition of P2X7R on cell proliferation using BrdU assay. First, cells were incubated with increasing concen-
trations of the general P2 receptor agonist ATP in the presence of control glucose concentrations (5.5 mM) or in 
high glucose (16.7 mM). Figure 7a shows that high glucose increased BrdU incorporation and adding exogenous 
ATP had no further effect. However, 10 and 100 μM ATP significantly increased BrdU incorporation in control 
Figure 5. Effect of P2X7R and glucose on calcium transients. Representative recordings of intracellular Ca2+ 
(given as Fura-2 ratio) in INS-1E cells stimulated with BzATP (10 μM). (a) BzATP induced synchronous Ca2+ 
peaks in 2.8 mM glucose solutions. (b) This response was abolished by short pre-treatment with the P2X7R 
inhibitor (AZ10606120, 10 μM). (c) In high glucose (16.7 mM) many cells showed Ca2+ oscillations and BzATP 
induced synchronized Ca2+ peak. (d) Pre-treatment with AZ10606120 abolished the Ca2+ peak response. Each 
graph shows responses of 10 cells/experiment and each experiment was performed 3–4 times. (e,f) Bargraphs 
show the peak change means ± s.e.m. in fura-2 ratio in response to BzATP with/without pre-treatment with 
AZ10606120 (10 μM) for the two glucose concentrations indicated. The graph also shows the responses to a 
depolarizing K+ step (30 mM), which was carried out at the end of most experiments. Numbers indicate the 
number of cells analyzed in 3–4 independent experiments. Significant differences, **p < 0.01, are indicated.
www.nature.com/scientificreports/
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low glucose conditions. In order to explore whether this effect of ATP was due to P2X7R activation, BzATP, a 
more specific P2X7R agonist, was applied (Fig. 7b). There was a tendency that BzATP 10–100 μM also increased 
BrdU incorporation, but no significance was reached on this data set. Notably, increasing BzATP concentration 
to 1000 μM markedly reduced BrdU incorporation, both in control condition and when applied together with 
high glucose. These concentration-dependent and seemingly opposite effects of BzATP are one of the signatures 
of P2X7R multifunctionality (see discussion).
In order to verify whether cell proliferation involves P2X7R, we next tested the effect of the two P2X7R 
inhibitors AZ10606120 (10 μM) and A438079 (10 μM) (Fig. 7c,d). The application of AZ10606120 significantly 
decreased BrdU incorporation both in control and in high glucose conditions (Fig. 7c), and application of 
A437980 diminished the proliferative effect of high glucose (Fig. 7d). In order to confirm the general involvement 
of extracellular ATP on cell proliferation, we also tested the effect of a potent ATP-diphosphohydrolase (apyrase 
10 U/ml) that hydrolyses ATP and ADP to AMP. As expected, apyrase inhibited BrdU incorporation in control 
and high glucose (Supplementary Fig. 1g). In contrast to P2X7R inhibitors, Panx1 inhibition seemed to have no 
effect on proliferation (Fig. 7e). Also mannitol was without significant effects on proliferation (Supplementary 
Fig. 1h).
Results in Fig. 7 indicate that high concentrations of BzATP (mM) and the P2X7R inhibitors decreased BrdU 
uptake by either decreasing proliferation or by promoting cell death. Therefore, we performed FACS analysis 
using Annexin V and propidium iodide and the apoptotic inducer AT101 as control (Fig. 7f). The data show that 
neither the high concentration of BzATP nor the inhibitors had cytotoxic effects on INS-1E cells. Therefore, the 
inhibitory effects of high concentration of BzATP, and P2X7R inhibitors, on BrdU incorporation were most likely 
due to suppression of cell proliferation.
Discussion
This study shows that INS-1E and β-cells express the P2X7 receptor, and this receptor regulates cell prolif-
eration and insulin secretion, as well as Ca2+ signaling and cell metabolism. The receptor also plays a role in 
glucose-stimulated ATP release, most likely via regulation of Panx1. Furthermore, we show for the first time that 
Panx1 is expressed in β-cells and plays an important role. The two proteins, P2X7R and Panx1, have key effects in 
β-cell functions as we discuss in detail below.
Our data show that INS-1E cells express the P2X7R, most likely the full length isoform A (Fig. 1). Other 
C-terminal truncated isoforms and one with alternative N-terminus has been detected in rodent cells57,58. In 
human cells, there are ten isoforms of P2X7R that may confer different functions26,59. INS-1E cells also express 
Figure 6. Effect of apyrase and AZ10606120 on glucose-induced calcium transients. (a) Increase in glucose 
(from 2.8 to 16.7 mM) induced calcium oscillations in many cells and these were reduced by introduction of 
apyrase (10 U/ml). BzATP (100 μM) had no, if any, effect while increase in K+ to 30 mM caused further increase 
in intracellular Ca2+. (c) Similar protocol as in (a) but instead of apyrase AZ10606120 (10 μM) was added to 
the bath. Oscillations in Ca2+ abated and Fura-2 ratio increased until medium was exchanged with fresh low 
glucose solution. (b, d) Bargraphs shows means ± s.e.m. of height of Ca2+ oscillations in 2.8 mM, 16.7 mM 
glucose with/without apyrase (b) or AZ10606120 (d). Numbers indicate the number of cells analyzed in 5 and 4 
independent experiments, respectively. Significant differences, **p < 0.01, are indicated.
www.nature.com/scientificreports/
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Panx1. Panx1 forms hexamers (pannexons), which are transmembrane channels able to release ATP13. Three iso-
forms have been detected: the full-size Panx1A targeted to the plasma membrane and two novel isoforms Panx1C 
and Panx1D that could potentially form heteromers with isoform Panx1A and regulate its function, as described 
by Li and coworkers53. Immunolocalization experiments show that Panx1 and P2X7R are expressed in INS-1E 
cells as well as in rat and mouse islets (Fig. 2). We can state that the two proteins are expressed in INS-1E cells but 
they seem to distribute differently, i.e. Panx1 is more clearly localized to the plasma membrane while distribution 
of P2X7R is more punctuate. However, using the available antibodies and snapshots of dead cells, we cannot 
conclude whether in stimulated living cells there could be potential co-localization or interaction of these two 
proteins, as for example in neuroblastoma cells60, or potential interaction with insulin granules during exocytosis.
Interestingly, expression of P2X7R and Panx1 are upregulated with high glucose within two days (Fig. 1). 
But already within seconds of exposure to glucose these proteins step into action. Exposure to glucose induces 
a fast (<20 s) and dose-dependent increase in ATP release from INS-1E cells as revealed by on-line ATP meas-
urements (Fig. 3). Part of the release is due to exocytosis of insulin-containing granules, where ATP is accu-
mulated by VNUT. Our evidence supporting this is that the ATP release was partly and significantly abolished 
by pre-incubation with glyoxylate, a putative VNUT inhibitor, and bafilomycin A. Vesicular ATP release is in 
Figure 7. Effect of P2X7R on cell proliferation and viability. Data show cell proliferation measured by BrdU 
incorporation after 24 h. The black and grey bars show the effect of glucose alone and the white columns 
show the effect of increasing concentrations of ATP or BzATP. The control is 5.5 mM glucose. (a,b) Effect 
of exogenous ATP and the P2X7R agonist BzATP on cell proliferation. (c–e) Effect of the P2X7R inhibitors 
AZ10602120 (10 μM) and A438079 (10 μM), and pannexin-1 inhibitor 10Panx on cell proliferation at 5.5 mM 
and 16.7 mM glucose. (f) Cell viability was assayed by FACS analysis with Annexin V as apoptotic marker and 
propidium iodide as marker for necrotic or dead cells. Cells were incubated for 24 h with 5.5 mM or 16.7 mM 
of glucose in combination with the AZ10606120, A438079 or BzATP. AT101 (apoptotic inducer) was included 
as control. Representative FACS plots are shown in Supplementary Fig. 2. The bars show means ± s.e.m. of the 
percentage of cells in the indicated populations for 4–5 experiments. Late apoptotic and necrotic cells are shown 
as one population. Data represent means ± s.e.m. and n denotes the number of independent experiments and 
significant differences *p < 0.05 and **p < 0.01 are indicated.
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agreement with other studies performed on various β-cell preparations6–9, and also on exocrine enzyme-secreting 
pancreatic acini61. However, most importantly, our experiments reveal that there is another pathway for ATP 
release that depends on the P2X7R and Panx1. Panx1 has been described as one of the important proteins respon-
sible for ATP release in other cell types and it can be regulated by various P2 receptors, including the P2X7R 
either via direct protein-protein interaction or by increase in intracellular calcium12,13,36,53. As discussed below, we 
propose that this is the positive feedback autocrine signal amplifying glucose-induced insulin release62.
In many cells, mechanical stress (shear stress) or cell volume changes can also cause significant ATP 
release11,63–65. This is also the case in INS-1E cells where shear stress, cell swelling and cell shrinkage induced ATP 
release (Fig. 3 and Supplementary Fig. 1). In particular, mannitol in equimolar concentrations as glucose caused 
cell shrinkage and induced ATP release which was not sensitive to P2X7R, Panx1 or VNUT inhibitors and thus 
utilized different release pathway to that of glucose-stimulated release. Glucose load had minimal effect on cell 
volume (Fig. 3d), because after it´s uptake it is rapidly metabolized as shown by the increased intracellular ATP 
content after stimulation with 16.7 mM glucose (Fig. 3g). In fact, it seems that glucose metabolism is, at least in 
part, required for ATP release, as a non-metabolizable analogue of glucose 3-OMG and the metabolic uncoupler 
FCCP significantly reduced both intracellular ATP and ATP release process (Fig. 3f,g). There are a number of 
studies that have been trying to resolve dynamics in β-cells metabolism, intracellular ATP/ADP levels, calcium 
signals and exocytosis (see below). Studies using fluorescence reporters like Perceval or luciferase show that there 
are sub-plasma membrane oscillations in ATP concentrations66–69. Origin of these oscillations in β-cells is still 
unresolved, but one proposal is that it is due to oscillatory glycolysis66. Using fluorescent ATP sensors on mouse 
pancreatic cells, Tanaka and colleagues70 showed that glucose induces an increase in cytosolic and mitochondrial 
ATP (takes about 50–100 s) before onset of calcium oscillations. Interestingly, another study which used similar 
ATeam sensors targeted to mitochondria of INS-1 832/13 cells shows that there was a small dip in mitochondrial 
ATP (in about 5–10 sec) before an increase71. The authors propose that the dip is due to increased cytoplasmic 
demand associated with elevated calcium. Our study indicates that this dip could be due to ATP release. In any 
case, these intracellular events are very fast, and in agreement with the fast transmembrane efflux of ATP we 
detect. Furthermore, our results show that in INS-1E cells the total intracellular ATP content (metabolism) cor-
relates with ATP release and this in turn has long-term effects on cell metabolism and cell proliferation, and that 
purinergic signaling is involved in all steps (Fig. 8).
The P2X7R is a ligand-gated ion channel that allows influx of calcium. Accordingly, in INS-1E cells the P2X7R 
agonist, BzATP, induced synchronized Ca2+ transients even at non-stimulating concentrations of glucose, as well 
as at high glucose concentrations (Fig. 5). This BzATP effect on Ca2+ transients was abolished by the P2X7R 
inhibitor AZ10606120. Most importantly, AZ10606120 and apyrase inhibited Ca2+ oscillations induced by 
high-glucose (Fig. 6) indicating that local ATP release and purinergic system contributes to autocrine signaling. 
However, we cannot explain how with longer incubations times AZ10606120 causes elevated Ca2+ levels. One 
explanation could be that reduced intracellular ATP (Fig. 3g) could decrease function of the Na+/K+-ATPase, 
Ca2+-ATPases and Na+/Ca2+ exchanger, which would lead to imbalance between Ca2+ influx and efflux and thus 
increased and dysregulated cellular Ca2+ levels.
Figure 8. Cell model for autocrine purinergic signaling in β-cells. Glucose enters the cell and is metabolized to 
ATP. On left side of the cell (in blue) we show the well-established events: closure of ATP-sensitive K+ channels 
leading to cell membrane depolarization, opening of voltage-sensitive Ca2+ channels and influx of Ca2+ that 
triggers exocytosis of insulin-containing granules. Granules also contain ATP which is accumulated by VNUT. 
Our study on INS-1E cells shows (in green) that ATP is also released via pannexin-1 (Panx1) and the process 
is regulated by the P2X7R. Extracellular ATP binds to the receptor and causes further influx of Ca2+ and 
potentiation of insulin secretion. The resulting amplification of the Ca2+ signal promotes additional exocytosis 
of secretory granules. The P2X7 receptor also regulates β-cell proliferation/survival. ATP can also be released 
by cell volume/stress, but since these have no effect on cell proliferation, one or more of the steps in the glucose 
uptake – metabolism – Panx1 - P2X7R – chain are missing.
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Notably, stimulation of the P2X7R with BzATP in INS-1E resulted in insulin secretion, both at low, 
non-stimulating glucose concentrations, and at high glucose concentrations, where it potentiated glucose effects 
(Fig. 4). In isolated rat islets, BzATP had similar potentiating effects at low glucose concentrations. Perhaps sur-
prisingly, AZ10606120 pre-treatment did not inhibit high glucose-stimulated insulin release in INS-1E cells, 
while there was a tendency of inhibition in isolated islets, though not significant. One explanation could be that 
pretreatment with this blocker also elevates the basal intracellular Ca2+ (Fig. 6c), which could maintain overall 
insulin secretion. Perhaps better time resolution of phasic insulin secretion could contribute to further under-
standing the role of the P2X7R. Another explanation could be that ATP/BzATP stimulate other P2 receptors that 
contribute to insulin secretion. Jacques-Silva et al.18 show that on human pancreatic β-cells apyrase and apyrase 
inhibitor had negative and positive effects on insulin secretion, respectively, and they proposed that in these cells 
P2X3 receptors were important in autocrine regulation of insulin secretion.
In addition to the short-term effects on calcium, ATP and insulin release, we show that P2X7R has a role in 
cell proliferation. Low concentrations of ATP (10–100 μM) significantly stimulated proliferation of INS-1E cells 
in 5.5 mM glucose. Since cell proliferation was also sensitive to the two P2X7R inhibitors, especially in high glu-
cose medium, it supports the idea that the P2X7R has trophic effects (Fig. 7). This is in agreement with increased 
expression of P2X7R in high-glucose medium (Fig. 1). In contrast to the P2X7R, Panx1 does not seem to be 
involved in cell proliferation, although expression of both isoforms Panx1A and Panx1D increased with chronic 
high-glucose load. While the P2X7R was originally described as a death receptor causing pore-formation and 
apoptosis/necrosis41,59, several recent studies show that the receptor can increase cell proliferation40,72–75. Whether 
this depends on cell type, particular isoform expression, sub-maximal stimulations or a combination of these 
is not yet clear. Many earlier studies, in particular on immune-reactive cells, show that overstimulation of the 
receptor (pro-longed exposure or high ATP concentrations) have been associated with cell death59,76. However, in 
INS-1E cells even 1 mM BzATP does not seem to kill the cells, it just decreases their proliferation in both low and 
high glucose concentrations (Fig. 7).
Taken together, this study shows that the P2X7R is expressed in INS-1E cells (and mouse and rat islets) and 
affects important cell functions such as ATP metabolism and release, Ca2+ oscillations, insulin secretion and cell 
proliferation. Therefore, one will need to consider function of this receptor in β-cells in normal physiological 
responses as well as in pancreas pathologies, e.g. diabetes, as P2X7R in immune cells is important in inflamma-
tory processes25,27,41. Additionally, the effect of P2X7R SNPs in glucose homeostasis should be considered. It is 
not yet clear whether the P2X7R signatures will be the same in human and rodent β-cells, as different isoforms 
may be directing β-cell behavior. In addition, our study reveals expression and function of Panx1 as an additional 
ATP release mechanism to exocytosis of insulin granules. Panx1 could be regulated by the P2X7R, e.g. via calcium 
signaling, and calcium influx through P2X7Rs could provide additional nudge to exocytosis of insulin granules 
(Fig. 7). This feedforward mechanism would potentiate insulin release and may be the mechanism that has been 
predicted by other studies. Lastly, the bi-phasic effect of P2X7R on proliferation/survival of INS-1E cells is quite 
remarkable and indicates that similar regulatory switches could exist in other β-cells types. It should be explored 
whether these would contribute to positive or negative functional outcome in β-cells originating from different 
species and native cells versus cultured cells. Certainly, above elements of purinergic signaling constitute novel 
mechanisms for regulation of β-cell mass and enhancement of insulin release and thus could be important targets 
for diabetes therapy.
Methods
Cell culture. The rat pancreatic β-cell line INS-1E (AddexBio, San Diego, CA) passage 30–70 was cultured 
in RPMI-1640 media supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, 10 mM 
HEPES, 1 mM sodium pyruvate and 50 μM 2-mercaptoethanol. Cells were cultured in a humidified atmosphere 
at 37 °C with 5% CO2 in air.
Animals. Male Sprague-Dawley rats (100–150 g) and C57BL/6J mice (20–30 g) were obtained from Taconic 
Biosciences (Ejby, Denmark). The animals had free access to food and water and were killed by cervical disloca-
tion; rats were stunned by hard blow on the head prior to cervical dislocation. All experiments were performed 
on euthanized animals. Animals were handled according to the guidelines in accordance with EU directive 
2010/63/EU on protection of animals used for scientific purposes and experimental protocols were approved by 
the Danish Animal Experiments Inspectorate (license nr. 2011/561-56).
ATP release. Extracellular ATP was monitored using luciferin/luciferase luminescence reaction in the extra-
cellular medium. INS-1E cells were plated (50,000 cells/well) on 96-well COSTAR white plates and grown in 
5.5 or 2.8 mM glucose 24 h before experiment. Cells were washed and allowed to rest in 65 μl of physiological 
buffer that contained (in mM): 140 NaCl, 1 MgCl2, 1.5 CaCl2, 0.4 KH2PO4, 1.6 K2HPO4, 10 HEPES and glucose 
was 5.5 or 2.8 mM in control conditions, pH 7.4. After 30 min 25 μl of luciferin/luciferase mix in physiological 
buffer (BioThema, ATP kit SL 144–041) was added. Cells were left to rest approximately 20 min or until the lumi-
nescence dropped below at least 500 relative luminescence units (RLU). After recording the baseline for 120 sec 
with low glucose buffer (5.5 or 2.8 mM), 10 μl of the stimulant was pipetted gently to avoid mechanical distur-
bances. Addition of a buffer containing the same concentration of glucose as in the well served as a “mechanical 
disturbance” control. The stimulants were buffers containing glucose, such that the final concentration of glu-
cose was 3.5, 5.5, 16.7 or 25 mM in the well. In addition, mannitol and the non-metabolizable glucose-analogue 
3-O-methylglucose (3-OMG) were tested. In some experiments cells were pre-incubated with one of the following 
inhibitors: AZ10606120 (10 μM, Tocris), A438079 (10 μM, Tocris), 10Panx (100 μM, Tocris) and FCCP (Carbonyl 
cyanide 4-(trifluoromethoxy)phenylhydrazone, 5 μM). Measurements were performed using plate mode at 20 sec 
sampling rate with 1 sec interval time at 37 °C in FLUOstar Optima (BMG, Labtech). All measurements were run 
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in triplicates and n indicates the number of independent experiments. For each experimental protocol a standard 
curve was made with ATP (ATP standard from BioThema) concentrations ranging from 10−10 to 10−5 M. The 
effect of all applied stimuli and inhibitors on luciferin/luciferase assay activity was tested independently on stand-
ard curves (in agreement with our earlier study63 no effects were observed). Cell numbers were determined by cell 
counting kit-8 (CCK-8) in parallel wells with same cell seeding, and the concentration of extracellular ATP was 
corrected to 106 cells per 1 ml. The results are presented as the difference between the basal concentration of extra-
cellular ATP (in 2.8 or 5.5 mM glucose) and the peak concentration of ATP after stimulation (ΔATP released).
Intracellular ATP measurements. INS-1E cells were treated as described above in “ATP release” assay. 
After 30 min rest in physiological buffer containing 5.5 mM glucose, cells were pre-incubated with FCCP (5 μM), 
10Panx (100 μM) or AZ10606120 (10 μM) and then stimulated 2 min with control buffer, 16.7 mM glucose or 
16.7 mM 3-OMG. Next, incubation buffer was removed, cells were permeabilized with digitonin (50 μM) and the 
amount of intracellular ATP was assessed using luciferin/luciferase luminescence reaction (BioThema, ATP kit 
SL 144–041).
Cell volume measurement. INS-1E cells were cultured 48 h in RPMI-1640 media (5.5 mM glucose) in 
μ-Dishes for Live Cell Analysis (ibidi, Germany). After 48 h cells were washed and left in physiological buffer 
(5.5 mM glucose) containing calcein-AM (5 μM, Molecular Probes C-1430). After 10 min incubation at room 
temperature cells were washed and suspended in physiological buffer and temperature was regulated at 37 °C. The 
fluorescent calcein signal (488 nm excitation, 500–540 nm emission) was detected using a confocal laser scanning 
microscope (SP5-X MP, Leica Microsystems). The following solutions were added: physiological control buffer 
such that the final concentrations were 5.5 mM glucose, 16.7 mM glucose or 16.7 mM mannitol and hypotonic 
solution (MilliQ water with 1 mM Mg2+ and 1.5 mM Ca2+ to achieve 50% dilution). The solutions had the follow-
ing osmolalities, respectively: 292 ± 2; 305 ± 1; 310 ± 1 and 152 ± 2.7 mOsm/kg (n = 3). The following microscope 
settings were used during the experiments; 63x oil objective (NA 1.4), zoom factor 3x, format 512 × 512, frame 
rate 3 sec/frame and speed 400 Hz. 2% laser power and gain 80–95 (HyD2 detection) were kept constant during 
the experiment.
RNA isolation and RT-PCR. INS-1E cells were cultured to confluence in a petri dish and RNA was extracted using 
RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. Primers used were as follows: P2X7 (354 bp), 
5′- GTGCCATTCTGACCAGGGTTGTATAAA-3′ (forward), 5′-GCCACCTCTGTAAAGTTCTCTCCGAT-3′ 
(reverse)77 and Panx1 (125 bp), 5′-TAAACCCCAGCTATGGAGCCA-3′ (forward), 5′-GGCGTCAGTAAAATCCCG 
TTC-3′ (reverse)78. 0.5 μg RNA per reaction was used in OneStep RT-PCR Kit (Qiagen) with amplification parameters 
as follows: one cycle at 50 °C for 30 min and one cycle at 95 °C for 15 min followed by 35 cycles at 94 °C for 1 min, 50 
(Panx1) or 59 °C (P2X7R) for 1 min, 72 °C for 1 min, and finally, one cycle at 72 °C for 10 min. All transcripts were run 
electrophoretically on 1.2% agarose gels.
Western blot. INS-1E cells cultured in petri dishes were treated with the indicated concentrations of glucose 
for 24 or 48 h prior to protein extraction. Protein lysate was prepared and samples were reduced by 10 min heat-
ing at 98 °C in the presence of 50 mM DTT (dithiothreitol). Protein (25 μg) was loaded on 10% polyacrylamide 
precast gels (Invitrogen) and transferred to PVDF membranes (Invitrogen) by blotting. Membranes were blocked 
with 5% skim milk solution in TBS-Tween (0.1%) buffer for 1 h at room temperature and incubated overnight at 
4 °C with primary antibody against P2X7R (1:500 rabbit polyclonal, Alomone APR-004), pannexin-1 (1:1000 rab-
bit polyclonal, Alomone ACC-234) and β-actin (1:1000 mouse monoclonal C4, Santa Cruz Sc-47778). The blots 
were incubated with appropriate secondary HRP-conjugated antibodies (1:2500) and developed with EZ-ECL 
(Biological Industries) and visualized on Fusion FX (Vilber Lourmat). Band intensity was calculated using Bio1D 
software.
Immunocytochemistry. INS-1E cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% 
TritonX-100 and 1% BSA and blocked with 2% BSA in PBS for 1 h. Pancreas was excised from sacrificed ani-
mals, fixed in 4% paraformaldehyde, embedded in paraffin. Paraffin sections were de-paraffinized, pretreated with 
citrate buffer and glycine buffer and blocking buffer. Subsequently, cells and pancreas sections were incubated 
with antibodies against P2X7R (1:50 to 1:500, Alomone APR-004), pannexin-1 (2–4 μg/ml, HPA016930, Atlas 
antibodies) and insulin (1:6000, Sigma I2018, K36AC10). Then the samples were incubated with the appropriate 
secondary antibody conjugated to Alexa 488 (green) or Alexa 568 (red). DAPI (1:400, Molecular Probes) was 
used as nuclear stain. Fluorescence was examined in Leica SP 5X MP confocal laser scanning microscope with 
40 × 1.3 NA or 63 × 1.4 NA objectives and images. Images were collected in sequential scans and analyzed in 
Leica LAS AF software. Region of interest encompassing whole cells were used for determination of Pearson’s 
correlation coefficients.
Cell proliferation. INS-1E cells were plated (6000 cells/well) in white, clear bottom 96-well plates (COSTAR) 
in RPMI-1640 media containing 5.5 mM glucose. After attachment for 24 h the indicated concentrations of 
ATP, 2′-3′-O-(4-benzoylbenzoyl)-ATP (BzATP), P2X7R inhibitors (10 μM AZ10606120 and 10 μM A438079) 
or ATP-diphosphohydrolase (10 U/ml Apyrase, Sigma A6132) were added alone or in combination with high 
glucose in serum-free media. Cell treated with P2X7R inhibitors were pre-incubated with the inhibitors 15 min 
before stimulation with glucose. The cells were left undisturbed for another 24 h at 37 °C in a humidified atmos-
phere with 5% CO2 before they were treated with the reagents from Cell Proliferation ELISA, BrdU chemilu-
minescence kit (Roche) according to the manufacturer’s instructions. All measurements were performed in 
triplicates. Luminescence was read in FLUOstar Optima (BMG, Labtech).
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Cell viability. Cell viability was estimated using flow cytometry and the Alexa Fluor® 488 annexin V/Dead Cell 
Apoptosis Kit (Life Technologies). INS-1E cells were cultured in 5.5 mM glucose for 24 h before treatment with 
the indicated combination of glucose and P2X7R agonists BzATP (100 μM or 1 mM) and inhibitors AZ10606120 
(10 μM) and A438079 (10 μM). The apoptotic inducer AT101 (5 μM) was used as negative control. At 24 h after 
stimulation cells were harvested and stained with Annexin V (488/499) and Propidium iodide (535/617) according 
to the manufactures protocol. A minimum of 20000 cells per sample were analysed with FlowSight imaging flow 
cytometer (Merck-Millipore) and IDEAS software was then used to calculate the percentage of live, apoptotic and 
necrotic populations. Electronic compensation was used to eliminate bleed through of fluorescence.
Insulin secretion from INS-1E cells. INS-1E were plated (200,000 cells per well) in a 24 well plate and 
left undisturbed for 72 h. Prior to the experiment, cells were kept 2 h in glucose-free culture medium. Cells were 
washed and pre-incubated 30 min in Krebs-Ringer bicarbonate HEPES buffer (KRBH) of the following com-
position (in mM): 135 NaCl, 3.6 KCl, 5 NaHCO3, 0.5 NaH2PO4, 0.5 MgCl2, 1.5 CaCl2, and 10 HEPES, pH 7.4, 
BSA (0.1%). Insulin samples were collected from the supernatant after static incubation for a 30 min period in 
1 ml of KRBH containing the indicated glucose concentrations alone or in the presence of BzATP (10 μM) or 
AZ10606120 (10 μM). Samples were stored at −20 °C until measurement of insulin. Samples were analyzed using 
Rat Insulin ELISA Kit (EMD Millipore) according to the manufacturer’s instructions and including all appropri-
ate standards and controls.
Insulin secretion from rat islets. Islets of Langerhans were isolated from euthanized adult male Sprague 
Dawley rats by retrograde perfusion of the pancreas79 with 0.5 mg/ml collagenase from Clostridium Histolyticum 
(Sigma, St. Louis, MO) in HBSS (Gibco) supplemented with 5 mM HEPES. The excised pancreas was trans-
ferred to HBSS containing 5 mM HEPES, 5 mM glycine and 0.165 mg/ml trypsin inhibitor from Glycine max 
(Sigma) and placed in 37 °C water bath until tissue was readily dissociated when shaken by hand. Digestion was 
terminated by addition of ice-cold HBSS with 0.4% BSA. Tissue was passed through a size 40 sieve and washed 
3 times by centrifugation at 200 g for 10 s followed by gradient centrifugation in Histopaque®-1077 at 1000 g 
for 25 min. The islets were washed twice and handpicked under a stereomicroscope. Islets where cultured for 
18 h in RPMI1640 medium containing 11 mM glucose, 10% FBS and 1% penicillin/streptomycin in a humidified 
atmosphere at 37 °C with 5% CO2 in air. 11–30 islets were transferred to 300 μl KRBH in low glucose for 2 h prior 
to addition of the indicated glucose concentrations alone or in the presence of BzATP (10 μM) or AZ10606120 
(10 μM). Insulin release was taken as the difference between insulin in the supernatant obtained before addition 
of test compounds and 30 min after addition. Samples were handled as described above.
Calcium signals. INS-1E cells were plated on WillCo glass bottom dishes and allowed to attach for 2–3 days. 
Cells were loaded with Fura-2 AM (2–3 μM) for 30 min in physiological buffer, gently washed and mounted in 
temperature regulated chamber (37 °C) and most experiments were conducted in standing-bath configuration to 
minimize the mechanically induced ATP release artifacts (see Supplementary Fig. 1a,b). Experimental solutions con-
tained 2.8 or 16.7 mM glucose and cells were stimulated with BzATP and ATP and some dishes were pre-incubated 
with the P2X7R inhibitor AZ10606120 (10 μM) or apyrase (10 U/ml). Changes in intracellular Ca2+ were followed 
in Nikon Eclipse Ti microscope with 40x NA1.4 objective. Fura-2 – loaded cells were illuminated at λex = 340 nm for 
80 ms and λex = 380 nm for 60 ms at 1 s intervals (integration of 60 ms for each λ and <1 ms for changing λ) using 
a TILL Polychrome monochromator. Emission was collected at 500 nm by an image-intensifying, charge - coupled 
device (CCD) camera (Andor X3 897) and digitized by FEI image processing system (Thermo Fischer Scientific). 
LA Live Acquisition software was used to both control the monochromator and the CCD camera. The intracellular 
Ca2+ was presented as the ratio of Fura-2 fluorescence signals recorded at 340/380 nm.
Statistics. Data are shown as mean ± standard error of the mean (s.e.m.) and n denotes the number of 
independent experiments. Sigma Plot 13 was used for the following analyses. Data were tested for normality. 
Normalized data were analyzed with One-sample t-tests, followed by correction for multiple comparisons with 
the Holm-Bonferroni method, when more than two different conditions were tested relative to the control. 
Non-normalized data were tested with Student’s t tests or One-way ANOVA followed by post-hoc Bonferroni 
tests. Significant differences *p < 0.05 and **p < 0.01 are indicated.
Data availability statement. The datasets generated during and/or analyzed during the current study are 
available from the corresponding author on reasonable request.
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